中信证券:首予国药控股“买入”评级 目标价27港元

新浪港股
17 Mar
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  中信证券发布研报称,首次覆盖国药控股(01099),给予“买入”评级,给予2025年9倍PE,对应目标价27港元。该行称,国药控股是国内医药分销行业龙头企业,其核心业务药品分销在行业集中度提高的背景下,保持稳健增长;公司器械板块占比逐步提升,在不断拓宽市场覆盖和合作渠道的同时,积极引入器械制造业务,前沿布局优势医疗器械荧光内窥镜和影像设备,随着监管对行业影响出清,公司器械板块业绩有望恢复增长;零售板块门店数量稳步提升、单店数据持续改善,稳居行业龙头地位。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10